Kim En Hyung, Kim Dong Min, Lee Ji Yeoun
Department of Dermatology, Bundang Jesaeng General Hospital, Seongnam, Gyeonggi, South Korea.
Department of Dermatology, College of Medicine, Chungbuk National University, Chungdae-ro 1, Seowon-Gu, Cheongju, Chungbuk, 28644, South Korea.
Dermatol Ther (Heidelb). 2022 May;12(5):1281-1286. doi: 10.1007/s13555-022-00739-5. Epub 2022 May 4.
Erlotinib (Tarceva) is a drug used for the treatment of non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations. Since EGFR is expressed in the skin, EGFR inhibitors commonly develop cutaneous side effects such as acneiform eruption, paronychia, telangiectasias, and abnormal eyelash growth. A 56-year-old man and a 46-year-old man visited the dermatology clinic complaining of yellowish papuloplaques and acneiform eruption on the face. They had been treated with erlotinib for lung cancer. Since patients using EGFR inhibitors are increasing, physicians should be aware that xanthomatous change can occur in severe acneiform eruptions after erlotinib treatment.
厄洛替尼（特罗凯）是一种用于治疗表皮生长因子受体（EGFR）突变患者的非小细胞肺癌的药物。由于EGFR在皮肤中表达，EGFR抑制剂通常会产生皮肤副作用，如痤疮样皮疹、甲沟炎、毛细血管扩张和睫毛异常生长。一名56岁男性和一名46岁男性因面部出现淡黄色丘疹斑块和痤疮样皮疹就诊于皮肤科诊所。他们因肺癌接受了厄洛替尼治疗。由于使用EGFR抑制剂的患者在增加，医生应意识到厄洛替尼治疗后严重痤疮样皮疹可能会出现黄色瘤样改变。
